Truist on Privia Health (PRVA): 'Improving growth visibility and a favorable risk-reward for LT investors'

Truist Securities analyst Jailendra Singh reiterated a Buy rating and $33.00 price target on Privia Health Group Inc (NASDAQ: PRVA).

The analyst commented: "Disciplined Growth, Durable Economics, Improving Visibility; We hosted Robert Borchert, SVP IR & Corporate Communications, for a two-day NDR in the Midwest. We walked away from the meetings incrementally more confident in the durability and visibility of the growth model, particularly around disciplined geographic expansion, provider conversion, and cash generation. Combined with strong free-cash-flow conversion, a net-cash balance sheet, and opportunistic but disciplined capital allocation, we view PRVA’s model as increasingly differentiated within value-based care, with improving growth visibility and a favorable risk-reward for long-term investors. Reiterate Buy."

For an analyst ratings summary and ratings history on Privia Health Group Inc click here. For more ratings news on Privia Health Group Inc click here.

Shares of Privia Health Group Inc closed at $21.21 yesterday.

You May Also Be Interested In

• Senate votes to halt Iran war unless Trump gets approval from Congress
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• SPS Commerce hires Morgan Stanley, explores sale - Reuters